By Ana Espino | Published on
May 12, 2026 | 4 min read
COVID-19 is a respiratory infection caused by SARS-CoV-2,
responsible for a global pandemic that led to millions of hospitalizations and
deaths. Severe forms of the disease can cause significant pneumonia, acute
respiratory failure, and may require oxygen therapy or mechanical ventilation.
At the beginning of the pandemic, very few effective
treatments were available against SARS-CoV-2, and patient management relied
mainly on supportive care. Remdesivir, an antiviral initially developed against
Ebola, was quickly identified as a potential candidate because of its action on
viral replication. However, its actual effectiveness in hospitalized patients
remained uncertain.
The main challenge was to determine whether an antiviral
such as remdesivir could truly improve the clinical course of patients already
hospitalized for COVID-19, and to identify at which stage of the disease it
would be most effective, particularly in patients requiring oxygen therapy or
mechanical ventilation. The aim of the study was therefore to evaluate the
efficacy and safety of remdesivir compared with placebo in a randomized
double-blind clinical trial.
Can remdesivir speed recovery ?
This study was randomized, double-blind, placebo-controlled,
and multicenter. A total of 1,062 hospitalized COVID-19 patients were included.
These patients had respiratory involvement requiring hospitalization, including
oxygen therapy or more severe respiratory failure.
Participants were divided into two groups: one group
received intravenous remdesivir, while the other received a placebo. The
primary outcome studied was the time to clinical recovery, defined as
sufficient improvement allowing hospital discharge or no longer requiring
oxygen or intensive care.
The findings demonstrated that patients treated with
remdesivir experienced a shorter recovery time than those receiving placebo.
The median recovery time was 10 days in the remdesivir group compared with 15
days in the placebo group, suggesting faster clinical improvement with
treatment.
The benefit appeared particularly marked in patients
requiring standard oxygen therapy but who had not yet been mechanically
ventilated. In contrast, among patients already on mechanical ventilation or in
critical condition, the effectiveness of remdesivir appeared much more limited.
The study also showed a trend toward reduced mortality in
patients treated with remdesivir. However, this reduction was not statistically
significant in the final analysis, meaning the study could not conclusively
demonstrate a survival benefit.
Regarding safety, serious adverse events were overall less
frequent in the remdesivir group than in the placebo group. The main reported
side effects included liver abnormalities, kidney impairment, and
gastrointestinal disorders, although the treatment was generally considered
well tolerated.
A real but moderate benefit
COVID-19 can progress to severe respiratory forms requiring
hospitalization, oxygen therapy, or even mechanical ventilation. The main
challenge was to demonstrate that an antiviral could genuinely improve the
clinical outcomes of already hospitalized patients and to identify which
patients were most likely to benefit.
This study aimed to evaluate the clinical efficacy and
safety of remdesivir in hospitalized COVID-19 patients. The findings show that
remdesivir modestly accelerates clinical recovery in hospitalized patients with
COVID-19, particularly in those requiring oxygen therapy without invasive
ventilation. However, its effect on mortality remains uncertain, especially in
the most severe cases.
This study was one of the first positive trials involving an
antiviral treatment for COVID-19 and contributed to the authorization of
remdesivir use in several countries. Future perspectives now focus on
identifying the optimal timing of administration, combining remdesivir with
other treatments such as anti-inflammatory drugs, and evaluating its
effectiveness across different patient profiles with COVID-19.
Read next : COVID-19
vaccines linked to longer survival in some cancer patients
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap
between research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and accessible.
Her mission: to accelerate knowledge sharing and empower evidence-based
decisions
